Literature DB >> 20625772

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Kentaroh Yamamoto1, Hiroshi Imamura, Yutaka Matsuyama, Yukio Kume, Hitoshi Ikeda, Gary L Norman, Zakera Shums, Taku Aoki, Kiyoshi Hasegawa, Yoshifumi Beck, Yasuhiko Sugawara, Norihiro Kokudo.   

Abstract

BACKGROUND: Alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ-carboxy prothrombin (DCP), and Golgi protein-73 (GP73) have been used or proposed as tumor markers for hepatocellular carcinoma (HCC).
METHODS: They were measured in 96 patients undergoing hepatectomy for HCC to investigate their treatment response and association with variables linked with tumor invasiveness and/or prognosis. Values at 1 month post-surgery in the 77 patients without recurrence within 6 postoperative months were adopted as those after surgery.
RESULTS: GP73 levels did not change after hepatectomy, but levels of other markers decreased and areas under receiver operating characteristic curves (95% CI) were: 0.64 (0.56-0.72), 0.63 (0.55-0.71), 0.79 (0.73-0.86), and 0.63 (0.55-0.71) for AFP, AFP-L3, DCP, and combination of AFP and AFP-L3, respectively. Cutoff points giving specificities of 96.1% (sensitivities at these points) were: 124 ng/mL (28.1%), 10% (21.9%), and 60 mAU/mL (52.1%), for AFP, AFP-L3, and DCP, respectively. The combination of AFP and AFP-L3 provided a sensitivity of 26.0% at a specificity of 96.1%. The increased DCP value was, or tended to be, associated with a larger tumor, vascular invasion, intrahepatic metastases, and a lower grade of tumor cell differentiation. Although similar associations were found between AFP and vascular invasion as well as a lower grade of tumor cell differentiation, no such relationship was found with AFP-L3.
CONCLUSIONS: DCP is a more effective tumor marker than AFP and AFP-L3. AFP-L3 showed comparable accuracy to AFP but no benefit was found in their combination. GP73 did not play a significant role in this context. Indices of tumor invasiveness were most closely associated with DCP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625772     DOI: 10.1007/s00535-010-0278-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  39 in total

1.  Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis.

Authors:  Chiaki Kagebayashi; Isao Yamaguchi; Ayumi Akinaga; Hiromichi Kitano; Kazunori Yokoyama; Masahiro Satomura; Tatsuo Kurosawa; Mitsuo Watanabe; Tomohisa Kawabata; William Chang; Chen Li; Luc Bousse; Henry G Wada; Shinji Satomura
Journal:  Anal Biochem       Date:  2009-02-27       Impact factor: 3.365

2.  GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.

Authors:  Jorge A Marrero; Patrick R Romano; Olga Nikolaeva; Laura Steel; Anand Mehta; Claus J Fimmel; Mary Ann Comunale; Anthony D'Amelio; Anna S Lok; Timothy M Block
Journal:  J Hepatol       Date:  2005-06-28       Impact factor: 25.083

3.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

Authors:  Ryosuke Tateishi; Haruhiko Yoshida; Yutaka Matsuyama; Norio Mine; Yuji Kondo; Masao Omata
Journal:  Hepatol Int       Date:  2007-12-29       Impact factor: 6.047

Review 4.  Serological markers of liver cancer.

Authors:  Man-Fung Yuen; Ching-Lung Lai
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-02       Impact factor: 3.043

5.  Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas.

Authors:  Marc-Oliver Riener; Frank Stenner; Heike Liewen; Christopher Soll; Stefan Breitenstein; Bernhard Cornelius Pestalozzi; Panagiotis Samaras; Nicole Probst-Hensch; Claus Hellerbrand; Beat Müllhaupt; Pierre-Alain Clavien; Marcus Bahra; Peter Neuhaus; Peter Wild; Florian Fritzsche; Holger Moch; Wolfram Jochum; Glen Kristiansen
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

6.  Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis.

Authors:  K Shimizu; T Taniichi; S Satomura; S Matsuura; H Taga; K Taketa
Journal:  Clin Chim Acta       Date:  1993-01-31       Impact factor: 3.786

7.  Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Authors:  Kiyoshi Hasegawa; Hiroshi Imamura; Masayoshi Ijichi; Yutaka Matsuyama; Keiji Sano; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2008-01-18       Impact factor: 3.452

8.  GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population.

Authors:  Jin-song Hu; De-wu Wu; Shuo Liang; Xiong-yin Miao
Journal:  Med Oncol       Date:  2009-04-28       Impact factor: 3.064

9.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

10.  Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases.

Authors:  Yanli Gu; Wenli Chen; Yu Zhao; Liyun Chen; Tao Peng
Journal:  Ann Clin Biochem       Date:  2008-11-13       Impact factor: 2.057

View more
  62 in total

Review 1.  The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC).

Authors:  Lifeng Wang; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2011-10-10       Impact factor: 11.530

Review 2.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Preoperative Predictors Including the Role of Inflammatory Indices in Predicting Early Recurrence After Re-resection for Recurrent Hepatocellular Carcinoma.

Authors:  Yuxin Guo; Darren W Chua; Ye-Xin Koh; Ser-Yee Lee; Peng-Chung Cheow; Juinn-Huar Kam; Jin-Yao Teo; Pierce K Chow; Alexander Y Chung; London L Ooi; Chung-Yip Chan; Brian K P Goh
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

Review 4.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 5.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

Review 6.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

7.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

8.  Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.

Authors:  Xin-Sen Xu; Kai Qu; Chang Liu; Yue-Lang Zhang; Jun Liu; Yan-Zhou Song; Peng Zhang; Si-Nan Liu; Hu-Lin Chang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

9.  Diagnostic value of serum Golgi protein 73 for HBV-related primary hepatic carcinoma.

Authors:  Guosheng Gao; Feibo Dong; Xiaozhen Xu; Airong Hu; Yaoren Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.